clinical trial · NCT07868354
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Novo Nordisk A/S·phase1·recruiting·n = 60
OverweightObesityType 2 DiabetesTirzepatideZenagamtide
brief summary
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.
started
Oct 8, 2026
primary completion
Sep 7, 2028
completion
Sep 7, 2028
last updated
Oct 16, 2026
official title
An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Tirzepatide to Zenagamtide
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol